Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies

References

• Millan MJ, Andrieux A, Bartzokis G, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7):485–515.
   PubMed Web of Science ®Google Scholar
• Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193.
   PubMed Web of Science ®Google Scholar
• Meyer N, MacCabe JH. Schizophrenia. Medicine. 2016;44(11):649–653.
   Google Scholar
• Vita A, Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018;31(3):246–255.
   PubMed Web of Science ®Google Scholar
• Kumar A, Yadav M, Parle M, et al. Potential drug targets and treatment of schizophrenia. Inflammopharmacology. 2017;25(3):277–292.
   PubMed Web of Science ®Google Scholar
• Maric NP, Jovicic MJ, Mihaljevic M, et al. Improving current treatments for schizophrenia. Drug Dev Res. 2016;77(7):357–367.
   PubMed Web of Science ®Google Scholar
• Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8):2087.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007;12(10):904–922.
   PubMed Web of Science ®Google Scholar
• Wong EH, Tarazi FI, Shahid M. The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol Ther. 2010;126(2):173–185.
   PubMed Web of Science ®Google Scholar
• Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616.
   PubMed Web of Science ®Google Scholar
• El-Mallakh P, Findlay J. Improving treatment adherence in schizophrenia. Curr Treat Options Psychiatry. 2016;3(2):119–132.
   Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568–575.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213.
   PubMed Web of Science ®Google Scholar
• Patel R, Chesney E, Taylor M, et al. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? Psychol Med. 2018;48(10):1616–1623.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Yamada S, Otsubo T, et al. Brexpiprazole for the treatment of schizophrenia in adults: an overview of its clinical efficacy and safety and a psychiatrist's perspective. Drug Des Devel Ther. 2020;14:5559–5574.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
   PubMed Web of Science ®Google Scholar
• Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–614.
   PubMed Web of Science ®Google Scholar
• Szabo M, Klein Herenbrink C, Christopoulos A, et al. Structure–activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D- receptor. J Med Chem. 2014;57(11):4924–4939.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1–6.
   PubMed Web of Science ®Google Scholar
• Das S, Barnwal P, Winston A B, et al. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6(1):39–54.
   PubMed Web of Science ®Google Scholar
• Citrome L. The ABC's of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211–1220.
   PubMed Web of Science ®Google Scholar
• Aladeen T, Westphal E, Lee Y, et al. The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: a case series. Perspect Psychiatr Care. 2018;54(4):507–513.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yu R, Cao X, et al. Bio-mimicking nanoparticles for targeted therapy of malignant melanoma. J Biomed Nanotechnol. 2019;15(5):993–1004.
   PubMed Web of Science ®Google Scholar
• Zhai J, Wang Y-E, Zhou X, et al. Long-term sustained release poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases. Drug Deliv. 2020;27(1):1283–1291.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Prajapati VD, Jani GK, Kapadia JR. Current knowledge on biodegradable microspheres in drug delivery. Expert Opin Drug Deliv. 2015;12(8):1283–1299.
   PubMed Web of Science ®Google Scholar
• Talegaonkar S, Mittal A, Parmar S, et al. Aripiprazole loaded polymeric biodegradable microspheres: formulation and in vitro characterization. J Dispersion Sci Technol. 2009;30(8):1198–1202.
   Web of Science ®Google Scholar
• Hiraoka S, Uchida S, Namiki N. Preparation and characterization of high-content aripiprazole-loaded core–shell structure microsphere for long-release injectable formulation. Chem Pharm Bull (Tokyo). 2014;62(7):654–660.
   PubMed Web of Science ®Google Scholar
• Guo W, Quan P, Fang L, et al. Sustained release donepezil loaded PLGA microspheres for injection: preparation, in vitro and in vivo study. Asian J Pharm Sci. 2015;10(5):405–414.
   Web of Science ®Google Scholar
• Hu L, Zhang H, Song W. An overview of preparation and evaluation sustained-release injectable microspheres. J Microencapsul. 2013;30(4):369–382.
   PubMed Web of Science ®Google Scholar
• An T, Choi J, Kim A, et al. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process. Int J Pharm. 2016;503(1–2):8–15.
   PubMed Web of Science ®Google Scholar
• Nahata T, Saini TR. D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. Drug Dev Ind Pharm. 2008;34(7):668–675.
   PubMed Web of Science ®Google Scholar
• Dhanka M, Shetty C, Srivastava R. Injectable methotrexate loaded polycaprolactone microspheres: physicochemical characterization, biocompatibility, and hemocompatibility evaluation. Mater Sci Eng C Mater Biol Appl. 2017;81:542–550.
   PubMed Web of Science ®Google Scholar
• Chaurasia S, Mounika K, Bakshi V, et al. 3-month parenteral PLGA microsphere formulations of risperidone: fabrication, characterization and neuropharmacological assessments. Mater Sci Eng C Mater Biol Appl. 2017;75:1496–1505.
   PubMed Web of Science ®Google Scholar
• Shang Q, Zhang A, Wu Z, et al. In vitro evaluation of sustained release of risperidone-loaded microspheres fabricated from different viscosity of PLGA polymers. Polym Adv Technol. 2018;29(1):384–393.
   Web of Science ®Google Scholar
• Shavi GV, Nayak UY, Reddy MS, et al. A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2017;75:535–544.
   PubMed Web of Science ®Google Scholar
• Guo Y, Yang Y, He L, et al. Injectable sustained-release depots of PLGA microspheres for insoluble drugs prepared by hot-melt extrusion. Pharm Res. 2017;34(10):2211–2222.
   PubMed Web of Science ®Google Scholar
• Ige PP, Agrawal K, Patil U. Enhanced in vitro dissolution of iloperidone using Caesalpinia pulcherrima mucoadhesive microspheres. Beni-Suef Univ J Basic Appl Sci. 2015;4(1):26–32.
   Google Scholar
• Maniyar AJ, Patel GM, Shelat PK, et al. Development and characterization of thermosensitive intranasal gel containing paliperidone loaded microspheres. J Young Pharm. 2016;8(4):368–377.
   Web of Science ®Google Scholar
• D'Souza S, Faraj JA, Giovagnoli S, et al. IVIVC from long acting olanzapine microspheres. Int J Biomater. 2014;2014:407065.
   PubMedGoogle Scholar
• Aydin O, Aydin B, Tezcaner A, et al. Study on physiochemical structure and in vitro release behaviors of doxycycline-loaded PCL microspheres. J Appl Polym Sci. 2015;132(14):1–13.
   PubMed Web of Science ®Google Scholar
• D’Souza SS, DeLuca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech. 2015;6(2):E323–E328.
   Google Scholar
• Vemuri S, Yu C-D, Pushpala S, et al. Drug release rate method for a liposome preparation. Drug Dev Ind Pharm. 2008;17(2):183–192.
   Google Scholar
• Zou Q, Yan R, Liu W, et al. A validated quantification method for brexpiprazole in dog plasma. J Chromatogr Sci. 2018;56(8):702–708.
   PubMed Web of Science ®Google Scholar
• Huang L, Hwang C-A, Fang T. Improved estimation of thermal resistance of Escherichia coli O157:H7, Salmonella spp., and Listeria monocytogenes in meat and poultry – the effect of temperature and fat and a global analysis. Food Control. 2019;96:29–38.
   Web of Science ®Google Scholar
• Zeng Y, Liu J, Liu W, et al. A new method for the estimation of absorption rate constant in two-compartment model by extravascular administration. J Pharm Sci. 2020;109(5):1802–1810.
   PubMed Web of Science ®Google Scholar
• Rawat A, Bhardwaj U, Burgess DJ. Comparison of in vitro–in vivo release of Risperdal(®) Consta(®) microspheres. Int J Pharm. 2012;434(1–2):115–121.
   PubMed Web of Science ®Google Scholar
• Mao S, Xu J, Cai C, et al. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm. 2007;334(1–2):137–148.
   PubMed Web of Science ®Google Scholar
• Xia Y, Pack DW. Uniform biodegradable microparticle systems for controlled release. Chem Eng Sci. 2015;125:129–143.
   Web of Science ®Google Scholar
• Tran VT, Benoit JP, Venier-Julienne MC. Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int J Pharm. 2011;407(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Cao X, Luo J, Gong T, et al. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharm. 2015;12(1):274–286.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu R, Fu Y, et al. Release mechanisms and applications of drug delivery systems for extended-release. Expert Opin Drug Deliv. 2020;17(9):1289–1304.
   PubMed Web of Science ®Google Scholar
• Zolnik BS, Burgess DJ. Evaluation of in vivo–in vitro release of dexamethasone from PLGA microspheres. J Control Release. 2008;127(2):137–145.
   PubMed Web of Science ®Google Scholar
• Andhariya JV, Burgess DJ. Recent advances in testing of microsphere drug delivery systems. Expert Opin Drug Deliv. 2016;13(4):593–608.
   PubMed Web of Science ®Google Scholar
• Holland SJ, Tighe BJ, Gould PL. Polymers for biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems. J Control Release. 1986;4(3):155–180.
   Google Scholar